MEDI 2452Alternative Names: MEDI-2452
Latest Information Update: 17 Nov 2014
At a glance
- Originator AstraZeneca
- Class Antibodies
- Mechanism of Action Platelet aggregation modulators; Purinoceptor P2Y12-modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemorrhage
Most Recent Events
- 13 Nov 2014 Preclinical trials in Haemorrhage in USA (unspecified route)